Head-to-head evidence
cagrilintide/semaglutide vs ZT002
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
cagrilintide/semaglutide · CagriSema
Developed by Novo Nordisk
NCT05394519 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.
Next expected readout: March 2027 · NCT07011667 (registry estimate)
ZT002
Developed by Beijing QL Biopharmaceutical
NCT07020884 · Phase 2 · completed
This randomized, double-blind, placebo-controlled Phase 2 trial (n=303) in adults with overweight or obesity found that ZT002 produced significantly greater weight loss than placebo at 24 weeks across all doses tested, up to 14.4% versus 2.4% with placebo (p<0.0001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT07443059 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: cagrilintide/semaglutide's landscape · ZT002's landscape